【０００１】[0001]
【発明の属する技術分野】本発明は、副腎皮質ホルモン
分泌抑制剤、ストレス緩和剤及びそれらを含有する組成
物に関する。TECHNICAL FIELD The present invention relates to a corticosteroid secretion inhibitor, a stress reliever and a composition containing them.
【０００２】[0002]
【従来の技術】現在はストレスの時代であり、現代社会
に生きる者が過剰のストレスを受けて生活していること
を否定する者はいない。この為、現代人の典型的な疾病
に、拒食症、不眠症、過食症、ノイローゼ、出社拒否症
等の心身症がある。これに対してこの様なストレスを軽
減するため、広くカラオケやいわゆるノミニケーション
が行われているが、この様な対処が健全でないことは言
うまでもない。ストレスを発散する手段としてスポーツ
があるが、多忙な中で無理に行うスポーツは効果が少な
いばかりか、心臓発作を招くなど危険な面が少なくな
い。この様な観点に於いて、無理無くストレスを緩和す
る手段が求められていた。2. Description of the Related Art Presently, it is an era of stress, and there is no denying that people living in modern society are living under excessive stress. Therefore, typical diseases of modern people include psychosomatic disorders such as anorexia nervosa, insomnia, bulimia nervosa, neurosis, and refusal to go to work. On the other hand, in order to reduce such stress, karaoke and so-called nomination are widely performed, but it goes without saying that such measures are not healthy. There are sports as a means to release stress, but sports that are forcibly performed during a busy period are not very effective, and there are many dangerous aspects such as causing a heart attack. From such a point of view, there has been a demand for means for relieving stress without difficulty.
【０００３】又、一方、副腎皮質ホルモンには、糖質コ
ルチコイドと鉱質コルチコイドの２種が存在し、これら
には種々の役割があるといわれている。例えば、糖質コ
ルチコイドは肝臓での糖新生が促進され血糖を上昇させ
たり、筋肉ではタンパク質の分解を促進したり、脂肪組
織では脂肪分解を促進し血中遊離脂肪酸量を増加させ
る。又、炎症による浮腫、毛細血管拡張、フィブリン沈
着、好中球遊走、喰作用、線維芽細胞増殖、肉芽形成等
が抑制するし、鉱質コルチコイドは腎遠位尿細管に作用
し、ナトリウムの再吸収を促進し、カリウム、水素イオ
ンの尿中排泄を促進する。このうち、糖質コルチコイド
はストレスと深く係わっている物質といわれており、ス
トレスを強く感じるとき血中へのこの糖質コルチコイド
の分泌量が増加すると言われている。しかし、ストレス
負荷状態に於いて、ハーブの香りの存在がどの様に糖質
コルチコイドの体液濃度に影響を与えるかは知られてい
ない。On the other hand, there are two types of adrenocortical hormones, glucocorticoids and mineralocorticoids, which are said to have various roles. For example, glucocorticoids promote gluconeogenesis in the liver to raise blood sugar, promote protein degradation in muscle, and promote lipolysis in adipose tissue to increase blood free fatty acid content. It also suppresses edema due to inflammation, telangiectasia, fibrin deposition, neutrophil migration, esophageal action, fibroblast proliferation, granulation, etc. Promotes absorption and promotes urinary excretion of potassium and hydrogen ions. Of these, glucocorticoids are said to be closely related to stress, and it is said that the amount of glucocorticoids secreted into blood increases when stress is strongly felt. However, it is not known how the presence of herbal aromas influences glucocorticoid body fluid concentration under stress.
【０００４】更に、ハーブに代表される香料などの効果
として抗ストレス効果があることは言われているが、そ
の効果を実際に確かめた例は知られていない。又、ハー
ブの好ストレス効果を定量化することは行われていな
い。更に、ハーブの内、シソ科の植物が抗ストレス作用
或いは糖質コルチコイド低下作用に優れていることも知
られていない。Further, although it is said that there is an anti-stress effect as an effect of a fragrance represented by an herb, there is no known example of actually confirming the effect. Also, no quantification of the positive stress effects of herbs has been done. Furthermore, it is not known that, among the herbs, plants of the Labiatae family are excellent in anti-stress action or glucocorticoid lowering action.
【０００５】[0005]
【発明が解決しようする課題】本発明はこの様な状況下
行われたものであり、手軽にストレスの指標である、副
腎皮質ホルモンの分泌を抑制し、体液中の副腎皮質ホル
モンの濃度を低下させる副腎皮質ホルモン分泌抑制剤を
提供することを課題とする。The present invention has been made under such circumstances, and easily suppresses the secretion of corticosteroids, which is an index of stress, and reduces the concentration of corticosteroids in body fluids. It is an object to provide a corticosteroid secretion inhibitor.
【０００６】[0006]
【課題を解決するための手段】本発明者等はこの様な状
況に鑑みて、手軽にストレスの指標である、副腎皮質ホ
ルモンの分泌を抑制し、体液中の副腎皮質ホルモンの濃
度を低下させる副腎皮質ホルモン分泌抑制剤を求めて各
種原料を対象にスクリーニング研究を重ねた結果、シソ
科植物のエッセンスにその様な作用を見いだし発明を完
成させた。以下本発明について詳細に説明する。In view of these circumstances, the present inventors can easily suppress the secretion of corticosteroids, which is an index of stress, and reduce the concentration of corticosteroids in body fluids. As a result of repeated screening research on various raw materials for an adrenocortical hormone secretion inhibitor, we found such an action in the essence of Lamiaceae plants and completed the invention. Hereinafter, the present invention will be described in detail.
【０００７】（１）本発明の副腎皮質ホルモン分泌抑制
剤 本発明の副腎皮質ホルモン分泌抑制剤はシソ科植物のエ
ッセンスからなる。シソ科植物としては、例えば、ラベ
ンダー、マージョラム、タイム、セイジ、バジル、ペパ
ーミント、スペアミント、キャットニップ、ローズマリ
ー、レモンバーム、オレガノ、ニホンハッカ、シソ等が
例示でき、これらの何れもが副腎皮質ホルモン分泌抑制
作用が期待できる。これらの内好ましいものは、ラベン
ダー、マージョラム、ミント、バジルであり、この中で
もラベンダー、マージョラム、ミントが更に好ましい。
本発明に言うエッセンスとは、これらの植物の植物体を
乾燥、細切、粉砕した加工品、植物体又はその加工品を
溶剤で抽出したり、抽出したものから溶剤を除去した抽
出物、植物体或いはその加工物を蒸留又は水蒸気蒸留し
た蒸留物、抽出物或いは蒸留物をカラムクロマトグラフ
ィーや液液抽出した精製物等の総称を意味する。ここ
で、水蒸気蒸留は通常の通り、植物体又はその加工物に
水蒸気を吹き込み、溜出分を冷却し水相と有機相に分
け、有機相を取れば良く、又、抽出は、植物体又はその
加工物に０．５〜１０倍量の溶剤を加え室温であれば数
日、沸点付近の温度であれば数時間浸漬すればよい。溶
媒としては、例えば、メタノールやエタノール等のアル
コール類、酢酸エチルや蟻酸メチル等のエステル類、ア
セトニトリル等のニトリル類、ジエチルエーテルやテト
ラヒドロフラン等のエーテル類、クロロホルムや塩化メ
チレン等のハロゲン化炭化水素類、アセトンやメチルエ
チルケトン等のケトン類等が例示できる。本発明ではこ
れらの何れもが利用可能であるが、これらの内好ましい
ものは、蒸留などによって得た、植物体構成成分のうち
の低沸点成分、即ち、沸点２００℃未満の成分である。
これは、本発明の副腎皮質ホルモン分泌抑制剤が香気に
よって嗅覚を介して刺激する場合が最も効果的で安全な
副腎皮質ホルモン分泌抑制作用を期待できるからであ
る。本発明の副腎皮質ホルモン分泌抑制剤は後記実施例
に示す如く、嗅覚を介して唾液中の副腎皮質ホルモンの
濃度を下げる作用を有する。(1) Adrenal Cortex Hormone Secretory Inhibitor of the Present Invention The adrenal cortex hormone secretagogue of the present invention comprises an essence of a Lamiaceae plant. Examples of Lamiaceae include, for example, lavender, marjoram, thyme, sage, basil, peppermint, spearmint, catnip, rosemary, lemon balm, oregano, Japanese peppermint, perilla, and the like, and all of these have an action of suppressing corticosteroid secretion. Can be expected. Among these, lavender, marjoram, mint and basil are preferable, and among them, lavender, marjoram and mint are more preferable.
The essence referred to in the present invention, the plant of these plants are dried, shredded, crushed processed product, the plant or a processed product thereof is extracted with a solvent, or an extract obtained by removing the solvent from the extracted product, a plant It means a general term for a distillate obtained by distilling or steam distilling a body or a processed product thereof, an extract or a purified product obtained by subjecting a distillate to column chromatography or liquid-liquid extraction. Here, steam distillation is usually performed by blowing steam into a plant or a processed product thereof, cooling the distillate to separate it into an aqueous phase and an organic phase, and taking an organic phase. A solvent in an amount of 0.5 to 10 times is added to the processed product, and it may be immersed for several days at room temperature and for several hours at a temperature near the boiling point. Examples of the solvent include alcohols such as methanol and ethanol, esters such as ethyl acetate and methyl formate, nitriles such as acetonitrile, ethers such as diethyl ether and tetrahydrofuran, halogenated hydrocarbons such as chloroform and methylene chloride. Examples thereof include ketones such as acetone and methyl ethyl ketone. In the present invention, any of these can be used, but among these, preferred is a low boiling point component of the plant constituent components, that is, a component having a boiling point of less than 200 ° C., obtained by distillation or the like.
This is because the corticosteroid secretion inhibitor of the present invention can be expected to have the most effective and safe corticosteroid secretion inhibitory action when it is stimulated by odor via the olfactory sense. The corticosteroid secretion inhibitor of the present invention has an action of lowering the concentration of corticosteroids in saliva via the olfactory sense, as shown in Examples below.
【０００８】（２）ストレスの負荷と副腎皮質ホルモン
の関係 ストレスと副腎皮質ホルモン、取り分け糖質コルチコイ
ドの関係は深いとされているが、これらを実際に確かめ
た例はない。そこで、糖質コルチコイドとしてコルチゾ
ールをとり、ストレスの負荷とコルチゾールの関係を知
るために次のような実験を行った。即ち、被験者２０名
を集め、２桁の加減乗除の計算を１題につき４秒の猶予
で３０分間行わせ、その前後３０分に唾液を採取し、唾
液中のコルチゾール濃度を後記発明の実施の形態に示す
ラジオイムノアッセイによって求めた。（（計算後のコ
ルチゾールの濃度）−（計算前のコルチゾールの濃
度））／（計算前のコルチゾールの濃度）＊１００の計
算式より唾液中コルチゾールの増加率を求めた。同様
に、それぞれ別の日に、猶予時間を３秒にした場合、問
題を解く時間を４０分間にした場合のこの値も求めた。
結果を表１に示す。この表よりストレスの負荷量に比例
してコルチゾールの増加率も上昇することが判る。即
ち、コルチゾールに代表される糖質コルチコイドの唾液
中への分泌量が負荷されているストレスの強さの指標に
なることが判る。即ち、コルチゾールに代表される糖質
コルチコイドの分泌量を下げる物質が、ストレスを緩和
しうる物質であるといえる。(2) Relationship between stress load and corticosteroids It is said that the relationship between stress, adrenocortical hormones, and especially glucocorticoids is deep, but there has been no actual confirmation of these. Therefore, cortisol was taken as a glucocorticoid, and the following experiment was conducted in order to know the relationship between stress load and cortisol. That is, 20 subjects were collected, and 2-digit addition, subtraction, multiplication, and division calculations were performed for 4 minutes per item for 30 minutes, saliva was collected 30 minutes before and after the calculation, and the cortisol concentration in saliva was measured according to the embodiment It was determined by the radioimmunoassay shown in the form. The increase rate of cortisol in saliva was calculated from the formula ((concentration of cortisol after calculation)-(concentration of cortisol before calculation)) / (concentration of cortisol before calculation) * 100. Similarly, on different days, this value was also obtained when the grace time was 3 seconds and the problem solving time was 40 minutes.
The results are shown in Table 1. From this table, it can be seen that the rate of increase in cortisol increases in proportion to the stress load. That is, it is understood that the secretion amount of glucocorticoid typified by cortisol into saliva can be an index of the stress intensity. That is, it can be said that a substance that reduces the secretion amount of glucocorticoid typified by cortisol is a substance that can relieve stress.
【０００９】[0009]
【表１】[Table 1]
【００１０】（３）本発明の副腎皮質ホルモン分泌抑制
剤の作用 本発明の副腎皮質ホルモン分泌抑制剤は、香りとして嗅
覚を刺激することにより、ストレスを緩和させる作用を
有し、その結果として唾液中の副腎皮質ホルモンの分泌
を抑制しその濃度を低下させる作用を有する。本発明の
副腎皮質ホルモン分泌抑制剤が香りとして、その効果を
発揮する用量は、０．０１〜１０ｍｇ／ｍ3であり、こ
の濃度で嗅覚を刺激するのが好ましい。本発明の基源植
物は何れも食用に広く用いられているので、この様な濃
度で毒性を発現する心配はない。(3) Action of the corticosteroid secretion inhibitor of the present invention The corticosteroid secretion inhibitor of the present invention has the action of relieving stress by stimulating the olfactory sense as a scent, and as a result, saliva. It has the effect of suppressing the secretion of corticosteroids and decreasing its concentration. The dose of the scent of the corticosteroid secretion inhibitor of the present invention to exert its effect is 0.01 to 10 mg / m3 , and it is preferable to stimulate the olfactory sense at this concentration. Since all the source plants of the present invention are widely used for food, there is no concern that toxicity will develop at such concentrations.
【００１１】（４）本発明の組成物 本発明の組成物は、上記副腎皮質ホルモン分泌抑制剤を
含有することを特徴とする。組成物の種類としては、嗅
覚を介して本発明の副腎皮質ホルモン分泌抑制剤による
刺激を伝達しうるものであれば特段の限定はなく、例え
ば、ポプリ、ルームフレグランス、香水、化粧水等の香
粧品、ガムやキャンディー等の食品、ジュースや清涼飲
料水等の飲料等が好ましく例示できる。本発明の組成物
では副腎皮質ホルモン分泌抑制剤以外に、これらの組成
物で通常用いられている任意成分を自由に用いることが
出来る。この様な任意成分としては、例えば、香粧品で
はワセリンやマイクロクリスタリンワックス等のような
炭化水素類、ホホバ油やゲイロウ等のエステル類、牛
脂、オリーブ油等のトリグリセライド類、セタノール、
オレイルアルコール等の高級アルコール類、ステアリン
酸、オレイン酸等の脂肪酸、グリセリンや１，３−ブタ
ンジオール等の多価アルコール類、非イオン界面活性
剤、アニオン界面活性剤、カチオン界面活性剤、両性界
面活性剤、エタノール、カーボポール等の増粘剤、防腐
剤、紫外線吸収剤、抗酸化剤、色素、粉体類等が挙げら
れるし、食品や飲料では、矯味矯臭剤、甘味料、酸味
料、油脂、増粘剤、乳化安定剤、水、炭酸、賦形剤、結
合剤などが挙げられる。又、これら組成物における本発
明の副腎皮質ホルモン分泌抑制剤の好ましい含有料であ
るが、香粧品では、０．０１〜６０重量％が好ましく、
０．０５〜４０重量％がより好ましく、０．１〜３０重
量％が更に好ましい。食品或いは飲料では、０．０１〜
３０重量％が好ましく、０．０５〜２０重量％がより好
ましく、０．１〜１０重量％が更に好ましい。これらの
組成物は通常知られている方法により製造できる。(4) Composition of the present invention The composition of the present invention is characterized by containing the adrenocortical hormone secretion inhibitor. The type of composition is not particularly limited as long as it can transmit the stimulus by the corticosteroid secretion inhibitor of the present invention via the olfactory sense, for example, fragrance such as potpourri, room fragrance, perfume, and lotion. Preferable examples include cosmetics, foods such as gum and candy, and beverages such as juice and soft drinks. In the composition of the present invention, in addition to the adrenocortical hormone secretion inhibitor, any component usually used in these compositions can be freely used. Examples of such optional components include hydrocarbons such as petrolatum and microcrystalline wax in perfumery and cosmetics, esters such as jojoba oil and gallow, beef tallow, triglycerides such as olive oil, cetanol, and the like.
Higher alcohols such as oleyl alcohol, fatty acids such as stearic acid and oleic acid, polyhydric alcohols such as glycerin and 1,3-butanediol, nonionic surfactants, anionic surfactants, cationic surfactants, amphoteric interfaces Activators, ethanol, thickeners such as carbopol, preservatives, ultraviolet absorbers, antioxidants, pigments, powders and the like, in foods and beverages, flavoring agents, sweeteners, acidulants, Examples include oils and fats, thickeners, emulsion stabilizers, water, carbonic acid, excipients, binders and the like. The preferred content of the corticosteroid secretion inhibitor of the present invention in these compositions is 0.01 to 60% by weight for cosmetics.
0.05-40 wt% is more preferable, and 0.1-30 wt% is still more preferable. For food or beverages, 0.01-
30% by weight is preferable, 0.05 to 20% by weight is more preferable, and 0.1 to 10% by weight is further preferable. These compositions can be manufactured by a generally known method.
【００１２】[0012]
【発明の実施の形態】以下に例を挙げて本発明の実施の
形態について詳細に説明するが、本発明がこれら例のみ
に限定を受けないことは言うまでもない。BEST MODE FOR CARRYING OUT THE INVENTION Embodiments of the present invention will be described in detail below with reference to examples, but it goes without saying that the present invention is not limited to these examples.
【００１３】例１（製造例） ラベンダーの乾燥全草１ｋｇを粉砕し、水蒸気蒸留にか
け水不溶分を集め、０．７ｇの副腎皮質ホルモン分泌抑
制剤１を得た。Example 1 (Production Example) 1 kg of dried lavender whole grass was crushed and subjected to steam distillation to collect water-insoluble matter, to obtain 0.7 g of corticosteroid secretion inhibitor 1.
【００１４】例２（製造例） ペパーミントの乾燥葉１ｋｇを粉砕し、水蒸気蒸留にか
け水不溶分を集め、１．１ｇの副腎皮質ホルモン分泌抑
制剤２を得た。Example 2 (Production Example) 1 kg of dried leaves of peppermint were crushed and subjected to steam distillation to collect water-insoluble matter, to obtain 1.1 g of a corticosteroid secretion inhibitor 2.
【００１５】例３（製造例） スペアミントの乾燥葉１ｋｇを粉砕し、水蒸気蒸留にか
け水不溶分を集め、０．８ｇの副腎皮質ホルモン分泌抑
制剤３を得た。Example 3 (Production Example) 1 kg of dried leaves of spearmint were crushed and subjected to steam distillation to collect water-insoluble matter, to obtain 0.8 g of corticosteroid secretion inhibitor 3.
【００１６】例４（製造例） マージョラムの乾燥葉１ｋｇを粉砕し、水蒸気蒸留にか
け水不溶分を集め、０．７ｇの副腎皮質ホルモン分泌抑
制剤４を得た。Example 4 (Production Example) 1 kg of dried leaves of marjoram were crushed and subjected to steam distillation to collect water-insoluble matter, to obtain 0.7 g of corticosteroid secretion inhibitor 4.
【００１７】例５（製造例） バジルの乾燥葉１ｋｇを粉砕し、水蒸気蒸留にかけ水不
溶分を集め、１．２ｇの副腎皮質ホルモン分泌抑制剤５
を得た。Example 5 (Production Example) 1 kg of dried basil leaves was crushed and subjected to steam distillation to collect water-insoluble matter, and 1.2 g of a corticosteroid secretion inhibitor 5
I got
【００１８】例６（製造例） レモンバームの乾燥葉１ｋｇを粉砕し、水蒸気蒸留にか
け水不溶分を集め、０．９ｇの副腎皮質ホルモン分泌抑
制剤６を得た。Example 6 (Production Example) 1 kg of dried leaves of lemon balm were crushed and subjected to steam distillation to collect water-insoluble matter, to obtain 0.9 g of corticosteroid secretion inhibitor 6.
【００１９】例７（製造例） セイジの乾燥葉１ｋｇを粉砕し、水蒸気蒸留にかけ水不
溶分を集め、０．８ｇの副腎皮質ホルモン分泌抑制剤７
を得た。Example 7 (Production Example) 1 kg of dried leaves of sage were crushed and subjected to steam distillation to collect water-insoluble matter, and 0.8 g of corticosteroid secretion inhibitor 7
I got
【００２０】例８（製造例） ローズマリーの乾燥葉１ｋｇを粉砕し、水蒸気蒸留にか
け水不溶分を集め、１．３ｇの副腎皮質ホルモン分泌抑
制剤８を得た。Example 8 (Production Example) 1 kg of dried leaves of rosemary were crushed and subjected to steam distillation to collect water-insoluble matter, to obtain 1.3 g of corticosteroid secretion inhibitor 8.
【００２１】例９（製造例） キャットニップの乾燥葉１ｋｇを粉砕し、水蒸気蒸留に
かけ水不溶分を集め、１．１ｇの副腎皮質ホルモン分泌
抑制剤９を得た。Example 9 (Production Example) 1 kg of dried leaves in the catnip were crushed and subjected to steam distillation to collect water-insoluble matter, to obtain 1.1 g of the corticosteroid secretion inhibitor 9.
【００２２】例１０（製造例） タイムの乾燥葉１ｋｇを粉砕し、水蒸気蒸留にかけ水不
溶分を集め、０．６ｇの副腎皮質ホルモン分泌抑制剤１
０を得た。Example 10 (Production Example) 1 kg of dried leaves of thyme were crushed and subjected to steam distillation to collect water-insoluble matter, and 0.6 g of corticosteroid secretion inhibitor 1
0 was obtained.
【００２３】例１１（製造例） オレガノの乾燥葉１ｋｇを粉砕し、水蒸気蒸留にかけ水
不溶分を集め、０．７ｇの副腎皮質ホルモン分泌抑制剤
１１を得た。Example 11 (Production Example) 1 kg of dried leaves of oregano were crushed and subjected to steam distillation to collect water-insoluble matter, to obtain 0.7 g of corticosteroid secretion inhibitor 11.
【００２４】例１２（製造例） 紫蘇の乾燥葉１ｋｇを粉砕し、３ｌのメタノールで２時
間還流し抽出し溶媒を溜去し、２．１ｇの副腎皮質ホル
モン分泌抑制剤１２を得た。Example 12 (Production Example) 1 kg of dried leaves of shiso were crushed, refluxed with 3 l of methanol for 2 hours for extraction, and the solvent was distilled off to obtain 2.1 g of the corticosteroid secretion inhibitor 12.
【００２５】例１３（製造例） ニホンハッカの乾燥葉１ｋｇを粉砕し、５ｌのメタノー
ルで２時間還流し抽出して溶媒を溜去し、２．５ｇの副
腎皮質ホルモン分泌抑制剤１３を得た。Example 13 (Production Example) 1 kg of dried leaves of Japanese peppermint were crushed, refluxed with 5 l of methanol for 2 hours for extraction, and the solvent was distilled off to obtain 2.5 g of corticosteroid secretion inhibitor 13.
【００２６】例１４〜２０（配合例） 表２に示す処方でルームフレグランスを製造した。即ち
処方成分を加熱溶解し、容器に流し込み固化させてルー
ムフレグランスを得た。Examples 14 to 20 (formulation examples) Room fragrances were produced according to the formulations shown in Table 2. That is, the prescription ingredients were melted by heating, poured into a container and solidified to obtain a room fragrance.
【００２７】[0027]
【表２】[Table 2]
【００２８】例２１〜２７（配合例） 表３に示す処方でカーフレグランスを製造した。即ち処
方成分を加熱溶解し、容器に詰め、芯を装着させてカー
ムフレグランスを得た。Examples 21 to 27 (compounding example) A car fragrance was produced according to the formulation shown in Table 3. That is, the prescription ingredients were melted by heating, packed in a container and fitted with a core to obtain a calm fragrance.
【００２９】[0029]
【表３】[Table 3]
【００３０】例２８〜３４ 表４に示す処方で化粧水を作成した。即ち処方成分を８
０℃で加熱攪拌可溶化し冷却して化粧水を得た。Examples 28 to 34 Lotions were prepared according to the formulations shown in Table 4. That is, 8 prescription ingredients
Toner was obtained by heating, stirring and solubilizing at 0 ° C. and cooling.
【００３１】[0031]
【表４】[Table 4]
【００３２】例３５〜４１（配合例） 表５の処方に従ってヘアトニックを作成した。即ち、処
方成分を秤込み、攪拌可溶化してヘアトニックを得た。Examples 35 to 41 (Formulation Example) Hair tonics were prepared according to the formulations shown in Table 5. That is, the formulation ingredients were weighed and solubilized with stirring to obtain a hair tonic.
【表５】[Table 5]
【００３３】例４２〜４８（配合例） 表６の処方に従ってキャンディーを作成した。即ち、処
方成分を１２０℃で加熱して一様にし、成型してキャン
ディーを得た。Examples 42 to 48 (Compounding Example) Candy was prepared according to the formulation shown in Table 6. That is, the prescription ingredients were heated at 120 ° C. to make them uniform, and molded to obtain a candy.
【００３４】[0034]
【表６】[Table 6]
【００３５】[0035]
実施例１ 例１〜例１３の副腎皮質ホルモン分泌抑制剤１〜１３に
ついて、副腎皮質ホルモン分泌抑制作用を調べた。被験
者２０名に対し、副腎皮質ホルモン分泌抑制剤１〜１３
の存在下、前述の猶予４秒、３０分間の計算負荷作業を
行わせた。コントロール群は香りの存在無しで行った。
この作業の前後に唾液を採取し、ガンマー・コートコー
チゾンを用いてコルチゾールの定量を行った。即ち、唾
液を−２０℃、２４時間で凍結させ、５℃に戻し３００
０ｃｐｍ、１５分で遠心分離し上清を取った。この上清
を測定直前まで−２０℃で保存した。キットのトレーサ
ー液１バイアルをキットの緩衝液１００ｍｌと良く混和
させトレーサー緩衝液とした。キットの抗体チューブそ
れぞれに検体、ブランクとして生理食塩水、コルチゾー
ルの標準液を２００μｌづつ入れた。これらのチューブ
それぞれにトレーサー緩衝液１ｍｌを加えた。トータル
カウント測定用チューブ（Ｔ１，Ｔ２）にトレーサー緩
衝液を１ｍｌづつ加えキャップをしてトータルカウント
チューブとした。これらのチューブを３７℃、４５分イ
ンキュベートした。内容液を除去し、ガンマーカウンタ
ーで全てのチューブの放射能を測定した。このうち標準
液に対する放射活性をプロットし、検量線を作成し、こ
の検量線より各検体中のコルチゾールの濃度を算出し
た。尚、比較品としては、森林の香気成分である青葉ア
ルコールと柑橘類に含まれる香気成分であるリナロール
を用いた。結果を表７に示す。表の数値の単位はμｇ／
ｄｌである。この表より本発明の副腎皮質ホルモン分泌
抑制剤は有意に唾液中のコルチゾールの濃度を低下させ
ていた。又、青葉アルコールやリナロールに比較しても
低下の度合いは高かった。又、この実験結果が定量的に
ハーブの抗ストレス効果を評価していることも明かであ
る。Example 1 With respect to the corticosteroid secretion inhibitors 1 to 13 of Examples 1 to 13, the corticosteroid secretion inhibitory action was examined. Corticosteroid secretion inhibitors 1 to 13 for 20 subjects
In the presence of, the calculation load work for 30 minutes was performed for 4 seconds described above. The control group was run without the presence of scent.
Saliva was collected before and after this work, and cortisol was quantified using gamma-coated cortisone. That is, saliva is frozen at -20 ° C for 24 hours and then returned to 5 ° C for 300 hours.
The mixture was centrifuged at 0 cpm for 15 minutes and the supernatant was collected. This supernatant was stored at −20 ° C. until immediately before the measurement. One vial of the tracer solution of the kit was mixed well with 100 ml of the buffer solution of the kit to obtain a tracer buffer solution. Each of the antibody tubes of the kit was charged with 200 μl of a specimen, a saline solution as a blank, and a standard solution of cortisol. 1 ml of tracer buffer was added to each of these tubes. 1 ml of the tracer buffer was added to the tubes for total count measurement (T1, T2), and the tubes were capped to obtain total count tubes. These tubes were incubated at 37 ° C. for 45 minutes. The contents were removed, and the radioactivity of all tubes was measured with a gamma counter. Among them, the radioactivity for the standard solution was plotted to prepare a calibration curve, and the concentration of cortisol in each sample was calculated from the calibration curve. As comparative products, green leaf alcohol, which is a fragrance component of forest, and linalool, which is a fragrance component contained in citrus fruits, were used. Table 7 shows the results. The unit of numerical values in the table is μg /
dl. From this table, the corticosteroid secretion inhibitor of the present invention significantly reduced the concentration of cortisol in saliva. Also, the degree of decrease was higher than that of green leaf alcohol or linalool. It is also clear that the results of this experiment quantitatively evaluate the anti-stress effect of herbs.
【００３６】[0036]
【表７】[Table 7]
【００３７】[0037]
【発明の効果】本発明によれば、手軽にストレスの指標
である、副腎皮質ホルモンの分泌を抑制し、体液中の副
腎皮質ホルモンの濃度を低下させることが出来る。INDUSTRIAL APPLICABILITY According to the present invention, it is possible to easily suppress the secretion of corticosteroids, which is an index of stress, and reduce the concentration of corticosteroids in body fluids.
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP8065472AJPH09227399A (en) | 1996-02-27 | 1996-02-27 | Suppressant for secretion of adrenocortical hormone |
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP8065472AJPH09227399A (en) | 1996-02-27 | 1996-02-27 | Suppressant for secretion of adrenocortical hormone |
| Publication Number | Publication Date |
|---|---|
| JPH09227399Atrue JPH09227399A (en) | 1997-09-02 |
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP8065472APendingJPH09227399A (en) | 1996-02-27 | 1996-02-27 | Suppressant for secretion of adrenocortical hormone |
| Country | Link |
|---|---|
| JP (1) | JPH09227399A (en) |
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2001322939A (en)* | 2000-05-11 | 2001-11-20 | Ichimaru Pharcos Co Ltd | Agent for preventing and ameliorating skin roughening due to stress |
| WO2002049600A1 (en)* | 2000-12-20 | 2002-06-27 | Quest International B.V. | Perfume compositions |
| WO2003013495A1 (en)* | 2001-08-08 | 2003-02-20 | Smothers Don L | Formulation and method for reduction of stress in meat-producing animals |
| EP1342489A1 (en)* | 2002-02-08 | 2003-09-10 | Johnson & Johnson Consumer Companies, Inc. | Method of affecting sleep and sleep-related behaviors |
| JP2004123655A (en)* | 2002-10-07 | 2004-04-22 | National Institute For Environmental Studies | Anxiolytic |
| US6830755B2 (en) | 1999-10-01 | 2004-12-14 | Johnson & Johnson Consumer Companies, Inc. | Method for relaxing human beings using personal care compositions |
| JP2005015440A (en)* | 2003-06-27 | 2005-01-20 | Herb Road Co | Antilipidemic agent and food or beverage containing the same |
| US6986747B2 (en) | 2002-01-29 | 2006-01-17 | Johnson & Johnson Consumer Companies | Method of measuring the stress or relaxation level of a mammal |
| WO2006006267A1 (en)* | 2004-07-07 | 2006-01-19 | House Wellness Foods Corporation | Antistress agent |
| EP2081582A1 (en)* | 2006-11-24 | 2009-07-29 | DSMIP Assets B.V. | Rosemary extracts, dietary and pharmaceutical compositions containing them and their uses |
| EP2120981A1 (en)* | 2006-11-24 | 2009-11-25 | Nestec S.A. | Prevention and treatment of disorders connected to impaired neurotransmission |
| JP2010500306A (en)* | 2006-08-09 | 2010-01-07 | ディーエスエム アイピー アセッツ ビー．ブイ． | Novel agonists for treating disorders related to impaired neurotransmission |
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6830755B2 (en) | 1999-10-01 | 2004-12-14 | Johnson & Johnson Consumer Companies, Inc. | Method for relaxing human beings using personal care compositions |
| JP2001322939A (en)* | 2000-05-11 | 2001-11-20 | Ichimaru Pharcos Co Ltd | Agent for preventing and ameliorating skin roughening due to stress |
| WO2002049600A1 (en)* | 2000-12-20 | 2002-06-27 | Quest International B.V. | Perfume compositions |
| WO2003013495A1 (en)* | 2001-08-08 | 2003-02-20 | Smothers Don L | Formulation and method for reduction of stress in meat-producing animals |
| US6986747B2 (en) | 2002-01-29 | 2006-01-17 | Johnson & Johnson Consumer Companies | Method of measuring the stress or relaxation level of a mammal |
| EP1342489A1 (en)* | 2002-02-08 | 2003-09-10 | Johnson & Johnson Consumer Companies, Inc. | Method of affecting sleep and sleep-related behaviors |
| JP2004123655A (en)* | 2002-10-07 | 2004-04-22 | National Institute For Environmental Studies | Anxiolytic |
| JP2005015440A (en)* | 2003-06-27 | 2005-01-20 | Herb Road Co | Antilipidemic agent and food or beverage containing the same |
| WO2006006267A1 (en)* | 2004-07-07 | 2006-01-19 | House Wellness Foods Corporation | Antistress agent |
| JP2010500306A (en)* | 2006-08-09 | 2010-01-07 | ディーエスエム アイピー アセッツ ビー．ブイ． | Novel agonists for treating disorders related to impaired neurotransmission |
| JP2014122215A (en)* | 2006-08-09 | 2014-07-03 | Dsm Ip Assets Bv | New agonist for therapy of disorder related to damaged neurotransmission |
| EP2081582A1 (en)* | 2006-11-24 | 2009-07-29 | DSMIP Assets B.V. | Rosemary extracts, dietary and pharmaceutical compositions containing them and their uses |
| EP2120981A1 (en)* | 2006-11-24 | 2009-11-25 | Nestec S.A. | Prevention and treatment of disorders connected to impaired neurotransmission |
| US20100317727A1 (en)* | 2006-11-24 | 2010-12-16 | Antoine De Saizieu | Rosemary extracts, dietary and pharmaceutical compostions containing them and their uses |
| US20120183635A1 (en)* | 2006-11-24 | 2012-07-19 | Dsm Ip Assets B.V. | Rosemary extracts, dietary and pharmaceutical compositions containing them and their uses |
| Publication | Publication Date | Title |
|---|---|---|
| JPH09227399A (en) | Suppressant for secretion of adrenocortical hormone | |
| JP2017048322A (en) | Essential oil extraction method and essential oil product containing the essential oil | |
| JP4889954B2 (en) | Fragrance composition for female hormone regulatory function adjustment | |
| JP2002265977A (en) | Perfume composition capable of activating sympathetic nerve | |
| CN102614101A (en) | Cosmetic composition containing amur corktree bark extract and preparation method and application thereof | |
| JP6175216B2 (en) | Preventive and therapeutic agents for arthritis | |
| JPH09227400A (en) | Suppressant for secretion of adrenocortical hormone | |
| KR101159265B1 (en) | Perfume composition made of Cheju nature Citrus and Cosmetic composition using the same | |
| WO2021080535A2 (en) | Memory booster essential oil mixture | |
| JP5404985B2 (en) | Fragrance composition for male hormone adjustment | |
| KR20180092599A (en) | Cosmetic composition using wild ginseng | |
| JP3615512B2 (en) | Lipase activity activator, skin external preparation containing the lipase activity activator, skin external preparation for slimming, and bath preparation for slimming | |
| JP2000212060A (en) | Cosmetic | |
| JP5836421B2 (en) | Hair growth composition, dermal papilla cell proliferation promoting composition, FGF-7 production promoting composition, VEGF production promoting composition, skin surface blood flow promoting composition and cosmetic | |
| KR20190072290A (en) | Manufacturing method of extract from elsholtzia splendens for cosmetic and manufacturing method of cosmetic compositions comprising extract from elsholtzia splendens | |
| JPH05286845A (en) | Cosmetic for preventing skin ageing | |
| KR102112731B1 (en) | Effective manufacture for deodorization of yuja seed oil utilizing natural gardenia jasminoides and Liquorice extract | |
| KR20110098367A (en) | Deodorant composition comprising turmeric extract | |
| JPH11343497A (en) | Cosmetic | |
| JPH0386809A (en) | Asparagus saponin-containing cosmetic composition | |
| CN118178270B (en) | Compound essential oil for controlling oil and growing hair and washing and caring product composition containing compound essential oil | |
| DE2165633C3 (en) | Isopropanol-containing chamomile extracts with improved odor | |
| Patel et al. | Extraction of herbal aroma oils from solid surface | |
| JP2008074814A (en) | Lipolysis promoter | |
| KR102869165B1 (en) | Composition for enhancing attention and concentration comprising extract of zanthoxylum piperitum |